Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) presents significant therapeutic challenges due to inherent resistance to conventional treatments.
• The CXCR2 receptor axis is implicated in tumor progression, inflammation, angiogenesis, and metastasis.
• Understanding the role of CXCR2 in PDAC resistance is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate the role of the CXCR2 axis in mediating resistance to gemcitabine chemotherapy in pancreatic ductal adenocarcinoma (PDAC).
• To evaluate the efficacy of combining gemcitabine with a CXCR2 antagonist (Navarixin) in overcoming PDAC therapy resistance.

Main Methods:

• Generation of gemcitabine-resistant (GemR) PDAC cell lines (T3M4, CD18/HPAF).
• Analysis of chemokine ligand expression (CXCL1, CXCL5, CXCL8) in parental and GemR cells.
• In vitro treatment of cell lines with gemcitabine and Navarixin.
• In vivo evaluation of combination therapy in parental and GemR PDAC xenograft models.

Main Results:

• Gemcitabine-resistant PDAC cells exhibited higher baseline expression of CXCL1, CXCL5, and CXCL8.
• Combination therapy with gemcitabine and Navarixin demonstrated enhanced antitumor and antimetastatic activity compared to monotherapy in xenograft models.
• Lower concentrations of gemcitabine plus Navarixin were more effective in GemR cell lines than higher gemcitabine concentrations alone.

Conclusions:

• The CXCR2 axis plays a critical role in PDAC's resistance to gemcitabine therapy.
• Targeting CXCR2 in combination with gemcitabine represents a promising therapeutic strategy to improve treatment outcomes for PDAC patients.
• This approach offers a potential method to overcome chemoresistance in pancreatic cancer.